NCT04463251 - Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

November 3, 2021

Study Completion Date

October 10, 2022

Conditions

Acute ST Segment Elevation Myocardial Infarction

Interventions

BIOLOGICAL

RPH-104 80 mg

solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial

DRUG

Placebo

Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial

Trial Locations (11)

University of Virginia Health System, Charlottesville

Cleveland Clinic, Cleveland

"State Budgetary Healthcare Institution of Moscow City Clinical Hospital named after V.V. Vinogradov of Moscow Healthcare Department", Moscow

"State Institution of Healthcare in Moscow City Clinical Hospital № 51 Moscow Health Department", Moscow

"Federal State Budgetary Institution National Medical Research Center for Cardiology of the Ministry of Healthcare of the Russian Federation", Moscow

"State Budgetary Healthcare Institution of Moscow City Clinical Hospital named after V.V. Veresaev of Moscow Healthcare Department", Moscow

"The State Budgetary Health Care Institution of the Yaroslavl Region Regional Clinical Hospital", Yaroslavl

"St. Petersburg State Budgetary Healthcare Institution Saint Martyr Elizabeth City Hospital", Saint Petersburg

Ryazan State Medical University n.a. academician I.P. Pavlov on the basis of Regional Clinical cardiology Dispensary, Ryazan

"State Autonomous Healthcare Institution of the Perm Territory City Clinical Hospital No. 4", Perm

VCU Health-Virginia Commonwealth University Health, Richmond